Guillem Pascual Pastó
Investigador
Research group
Guillem Pascual-Pasto is currently a Researcher at the Institut de Recerca Sant Joan de Déu (IRSJD), where he leads a research line focused on the development of new immunotherapies for childhood cancer. His academic background includes studies in molecular and cellular biology, immunology, and preclinical models, with a career oriented toward translational research in pediatric oncology.
He completed his PhD at IRSJD under the supervision of Dr. Ángel M. Carcaboso (2013-2018), where he developed innovative retinoblastoma models and demonstrated the preclinical efficacy of new therapies, including oncolytic viruses that contributed to the initiation of clinical trials in humans. He subsequently carried out his postdoctoral training at the Children's Hospital of Philadelphia (CHOP, USA), in the laboratory of Dr. Kristopher R. Bosse (2018-2025), focusing on the development of advanced immunotherapies for neuroblastoma, such as next-generation CAR-T cells, antibody-drug conjugates, and lipid mRNA nanoparticles.
Throughout his career, he has secured competitive funding as Principal Investigator from several international institutions, including Alex's Lemonade Stand Foundation, Kate Amato Research Foundation, and the RNA Institute at the University of Pennsylvania. He has recently been awarded the prestigious Ramón y Cajal fellowship under a talent recruitment program to return to IRSJD, supporting his incorporation and consolidation as an independent researcher in Spain.
He is the lead author of publications in high-impact international journals such as Science Translational Medicine, Nature Communications, Clinical Cancer Research, and Journal for Immunotherapy of Cancer, among others. His career has been recognized with several prestigious awards, including the Schweisguth Prize from the International Society of Paediatric Oncology (SIOP), as well as the Emerging Innovator in Collaborative Science and the Global Scientific Excellence Award granted by the Children's Hospital of Philadelphia.
Professional network profiles
Last Publications
- Pascual-Pastó G, McIntyre B, Giudice AM, Alikarami F, Morrissey A, Matlaga S, Hofmann TJ, Burgeño-Sandoval V, Harvey K, Martinez D, Shah AC, Foster JB, Pogoriler J, Eagle RC, Carcaboso AM, Shields CL, Leahey AM and Bosse KR Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells CLINICAL CANCER RESEARCH . 30(16): 3578-3591.
- Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma PEDIATRIC BLOOD & CANCER . 71(1): .
- Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408.
Projects
- Project name:
- Next-generation immunotherapies for pediatric solid tumors
- Leader
- Guillem Pascual Pastó
- Funding entities:
- Ministerio De Ciencia E Innovacion
- Code
- RYC2024-048764-I
- Starting - finishing date:
- 2026 - 2030
- Project name:
- SGR 2017_Grup de Recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2017 SGR 01672
- Starting - finishing date:
- 2017 - 2021
- Project name:
- Caracterización y relevancia del entorno epigenético en el desarrollo del sarcoma de Ewing
- Leader
- Jaume Mora Graupera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI16/00245
- Starting - finishing date:
- 2017 - 2020